LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.
作者信息
Lee Rachael Chang, Thapa Bibhusal, John Thomas
机构信息
Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Australia.
出版信息
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S239-S242. doi: 10.21037/tlcr.2018.09.01.
Abstract
摘要
相似文献
1
LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S239-S242. doi: 10.21037/tlcr.2018.09.01.
2
Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
ESMO Open. 2020 Mar;5(2). doi: 10.1136/esmoopen-2020-000679.
3
Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
Eur Respir Rev. 2015 Jun;24(136):340-55. doi: 10.1183/16000617.00005814.
4
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Int J Clin Exp Pathol. 2015 May 1;8(5):5509-18. eCollection 2015.
5
Systemic and targeted therapies for early-stage lung cancer.
Cancer Control. 2014 Jan;21(1):21-31. doi: 10.1177/107327481402100104.
6
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.
Lung Cancer. 2012 May;76(2):138-43. doi: 10.1016/j.lungcan.2011.11.012. Epub 2011 Dec 6.
7
[Effectiveness of adjuvant chemotherapy in patient with early stages of non-small cell lung cancer depending on proliferation index of tumor].
Lik Sprava. 2014 Jan-Feb(1-2):110-7.
8
HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
J Cancer Res Clin Oncol. 2014 Aug;140(8):1441-9. doi: 10.1007/s00432-014-1687-2. Epub 2014 Apr 27.
9
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Ann Oncol. 2017 Apr 1;28(4):882-889. doi: 10.1093/annonc/mdx003.
10
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
Cancers (Basel). 2021 Apr 23;13(9):2046. doi: 10.3390/cancers13092046.
引用本文的文献
1
Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy.
J Thorac Dis. 2020 Jul;12(7):3715-3724. doi: 10.21037/jtd-20-2098.
本文引用的文献
1
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
2
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
3
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
J Clin Oncol. 2017 Jun 20;35(18):2018-2027. doi: 10.1200/JCO.2016.71.2893. Epub 2017 Apr 28.
4
Tracking the Evolution of Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.
5
Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.
Genes Chromosomes Cancer. 2017 Jul;56(7):559-569. doi: 10.1002/gcc.22460. Epub 2017 May 4.
6
The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy.
Clin Transl Sci. 2016 Dec;9(6):283-292. doi: 10.1111/cts.12429. Epub 2016 Nov 15.
7
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Ann Oncol. 2016 Nov;27(11):2004-2016. doi: 10.1093/annonc/mdw321. Epub 2016 Aug 8.
8
High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.
Oncotarget. 2016 Mar 22;7(12):13388-99. doi: 10.18632/oncotarget.7796.
9
Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling.
BMC Med Genomics. 2015 Feb 18;8:5. doi: 10.1186/s12920-015-0079-z.
10
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
Zotero 插件